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Abstract
Background: Mitochondrial neurogastrointestinal encephalopathy (MNGIE), due to mutations in TYMP, often presents
with gastrointestinal symptoms. Two sisters, initially managed for Crohn’s disease based upon clinical, imaging and
pathological findings, were later found to have MNGIE. The cases provide novel clinicopathological insight, for two
further reasons: both sisters remain ambulant and in employment in their late 20s and 30s; diagnosis in one sister was
made after a suspected azathioprine-precipitated acute illness.
Case presentation: A 25-year-old female presented with diarrhoea, vomiting, abdominal pain, and bloating. Faecal
calprotectin, colonic biopsies and magnetic resonance enterography were consistent with a diagnosis of Crohn’s
disease. Azathioprine initiation preceded admission with a sore throat, headache, myalgia, and pyrexia. Withdrawal led
to rapid clinical improvement. MRI brain revealed persistent, extensive white matter changes. Elevated plasma and
urine thymidine and deoxyuridine, and genetic testing for TYMP variants, confirmed MNGIE. Testing of the patient’s
sister, also diagnosed with Crohn’s disease, revealed identical variants. In this context, retrospective review of colonic
biopsies identified histological findings suggestive of MNGIE.
Conclusions: Azathioprine interference in nucleic acid metabolism may interact with the mitochondrial DNA depletion
of MNGIE. Nucleotide supplementation, proposed for treatment by manipulating mitochondrial nucleoside pools, may
require caution. The late onset and mild phenotype observed confirms presentation can occur later in life, and may
reflect residual thymidine phosphorylase activity. Clinicians should consider measuring plasma thymidine levels in
suspected Crohn’s disease to rule out MNGIE, particularly if white matter abnormalities are identified on neuroimaging.
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Background
Mitochondrial neurogastrointestinal encephalopathy (MN
GIE) is an autosomal recessive mitochondrial disorder
caused by mutations in TYMP leading to reduced thymi-
dine phosphorylase activity and high thymidine levels [1].
Multisystem sequelae include severe gastrointestinal dys-
motility [2], as well as cachexia, ptosis, ophthalmoparesis,
peripheral neuropathy and leukoencephalopathy. Symp-
toms typically present before age 20, and untreated,
progress relentlessly, with high mortality between the ages
of 20 and 40 [3].
All information about the two cases was extracted
retrospectively from clinical records. The UK IBD Gen-
etics Consortium dataset of 2513 patients with Crohn’s
disease who have undergone whole genome sequencing,
was used within a focused, retrospective search [4].
Case presentation
A 27-year-old white-British female (Patient 1) born to
non-consanguineous parents developed intermittent epi-
sodes of diarrhea, vomiting and abdominal cramps aged
18, associated with significant weight loss. Symptoms
* Correspondence: pfc25@cam.ac.uk
Presented at the British Society of Gastroenterology annual meeting, 2017 in
poster format.
3MRC Mitochondrial Biology Unit, University of Cambridge, Wellcome Trust /
MRC Building, Cambridge Biomedical Campus Hills Road, Cambridge CB2
0XY, UK
4Department of Clinical Neurosciences, University of Cambridge, Biomedical
Campus, Cambridge CB2 0QQ, UK
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Patel et al. BMC Gastroenterology           (2019) 19:11 
https://doi.org/10.1186/s12876-018-0925-5
were initially presumed to be post-infectious, given her
extensive travel history to Sub-Saharan Africa, South
America and South-East Asia. This first episode resolved
spontaneously.
Aged 25, she represented with diarrhoea, vomiting,
abdominal pain and bloating. Family history was notable
for an elder sister (Patient 2) with a diagnosis of Crohn’s
disease. Faecal calprotectin was significantly raised (> 600;
ref. 0–50⎧g/g). Tissue transglutaminase IgA antibody, ser-
ial stool samples for faecal culture, ova, cysts and parasites,
and Clostridium Difficile toxin testing, were negative.
Gastroscopy revealed appearances consistent with a dilated
second part of the duodenum in keeping with possible
small bowel obstruction. Colonoscopy was challenging due
to a sharply angulated sigmoid colon and significant
patient discomfort. Despite multiple attempts, it was not
possible to intubate and biopsy the terminal ileum. Colonic
biopsies obtained showed a panproctocolitis compatible
with inflammatory bowel disease (IBD) (Fig. 1a). Magnetic
resonance (MR) enterography identified a 2 cm segment of
terminal ileum with mural thickening and oedema and
intermediate enhancement. There was separation of bowel
loops in the distal ileal mesentery suggestive of fat prolifer-
ation. The remainder of the small bowel and large bowel
were normal, with no enlarged nodes, free fluid or fluid
collection (Fig. 1c-e).
A diagnosis of Crohn’s disease was made based on clin-
ical, radiological and pathological findings. Treatment with
budesonide and, subsequently, azathioprine was initiated.
Four weeks after commencing azathioprine, the patient
developed sore throat, headache, myalgia, and pyrexia of
41.1 °C.
On examination, she was of short stature with general-
ized sarcopaenia. BMI was 16.5 kg/m [2]. Cardiovascular,
respiratory and abdominal examinations were normal
with no extraintestinal manifestations of IBD. Higher
cognitive function was normal. Cranial nerve, upper and
lower limb, and cerebellar examinations were all normal
except for depressed reflexes.
She was treated for presumed meningoencephalitis
with empirical broad-spectrum intravenous antibiotics
and aciclovir, which were stopped following receipt of
sterile blood, urine and cerebrospinal fluid cultures.
Echocardiography and CT chest/abdomen/pelvis were
unremarkable. Withdrawal of azathioprine during ad-
mission led to rapid clinical improvement and apyrexia.
Persistent headaches during the episode led to an MRI
brain examination (Fig. 1f), revealing extensive white mat-
ter changes that persisted six weeks after stopping azathio-
prine (Fig. 1g). Subsequent metabolic investigations
identified elevated plasma lactate (5.2mM), plasma ammo-
nia (56mM), plasma thymidine (10⎧M) and deoxyuridine
Fig. 1 Colonic histology, MR enterography, and MRI brain for Patient 1 (a-g). (a) Colonic biopsy showing active inflammation in keeping with
panproctocolitis, H&E stain, magnification × 40. (b) Colonic biopsy showing focal atrophic changes within the smooth muscle cells of the
muscularis mucosa, including intracytoplasmic vacuoles, pyknotic nuclei and eosinophilic degeneration of the cytoplasm, H&E stain, magnification
× 200. (b-e) Coronal contrast MRI of the small bowel demonstrating a 2 cm segment of terminal ileum with mild mural thickening (c), mural
oedema on T2 sequence (d), intermediate enhancement with gadolinium (e), and separation of bowel loops in the distal ileal mesentery
suggesting fat proliferation. (f) Axial brain flair MRI taken during the acute admission, showing extensive confluent, symmetrical white matter
hyperintensity in both cerebral hemispheres, which does not show restricted diffusion. This extends from the periventricular to the subcortical
regions but sparing the U-fibres. (g) Follow-up axial brain flair MRI with contrast, at six weeks post-discharge, showing no change in the extent of
diffuse periventricular and subcortical white matter hyperintensity
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(15⎧M), and elevated urine thymidine (0.228mM) and
deoxyuridine (0.203mM), consistent with thymidine phos-
phorylase deficiency. Genetic testing revealed two heterozy-
gous TYMP variants: c.401C >A p.(Ala134Glu) [reported
previously [3]] and c.845G >A p.(Gly282Asp) [novel
variant], confirming diagnosis of MNGIE. Two years after
stopping azathioprine, the patient is well with no active
neurological or gastrointestinal symptoms.
Her elder sister (Patient 2) had a longstanding history of
diarrhoea with nocturnal symptoms, lethargy, loud borbo-
rygmi after eating and difficulty maintaining weight. She
too had been diagnosed with Crohn’s disease aged 34
following a colonoscopy that had identified aphthous ulcer-
ation in her descending colon (Fig. 2a) and biopsy findings
consistent with inflammatory bowel disease (Fig. 2b). She
had also been treated with budesonide and azathioprine
with no improvement in her symptoms. Additionally, she
had undergone brain MRI as a healthy control subject for a
clinical trial, which identified an incidental leukoencephalo-
pathy (Fig. 2d). Examination at age 38 revealed bilateral
ptosis, reduced upwards gaze and lateral eye movements,
generalized sarcopaenia, a mild waddling gait and modified
Gowers’ manoeuvre. Speech and cognition were normal.
Peripheral tone and power were normal. She was areflexic.
There were no cerebellar signs. Her BMI was 14.9 kg/m [2].
Subsequent investigations identified elevated plasma
thymidine (15 M) and deoxyuridine (21⎧M) and elevated
urine thymidine (0.6mM) and deoxyuridine (0.634mM).
Genetic testing identified the presence of the same two
TYMP variants c.401C >A p.(Ala134Glu) and c.845G >A
p.(Gly282Asp). In the context of having identified TYMP
variants, and the common absence of specific histological
features of Crohn’s disease, a further retrospective review
of colonic biopsies from both patients identified features
also suggestive of MNGIE [5] (Fig. 1b, 2c).
Discussion and conclusions
The family described are notable for three reasons.
Firstly, both sisters initially had a working diagnosis of
Crohn’s disease. Secondly, both sisters remain ambulant
and in employment in their late 20s and 30s, which may
reflect that the heterozygous TYMP variants identified
in these cases manifest as milder forms of the disease.
To date, both patients remain clinically stable under
supportive management, although allogeneic stem cell
transplantation has been discussed as a potential treat-
ment should they deteriorate in the future. Thirdly, diag-
nosis of MNGIE in Patient 1 was made after an acute
illness, possibly precipitated by initiation of azathioprine.
A previous publication identified three MNGIE pa-
tients out of a cohort of 102 who had been initially given
a working diagnosis of Crohn’s disease [3]. We searched
the UK IBD Genetics Consortium dataset of 2513
patients with Crohn’s disease who have undergone whole
genome sequencing, for evidence of patients in this
cohort who might have been mis-diagnosed as having
Fig. 2 Colonoscopic image, colonic histology, and MRI brain for Patient 2 (A-F). (a) Colonoscopy showing aphthous ulceration in the descending colon.
(b) Colonic biopsy showing patchy increase in chronic inflammatory cells within the lamina propria and focal cryptitis, H&E stain, magnification × 40.
(c) Colonic biopsy showing multiple, round and refractile eosinophilic cytoplasmic inclusions of megalomitochondria within the submucosal
ganglionic cells, H&E stain, magnification × 400. (d) Axial brain TSE MRI for Patient 2 with white matter changes, as described for Patient 1 Fig. 1f and g
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Crohn’s disease where the true diagnosis was MNGIE
[4]. None of these subjects had homozygous or
compound heterozygous loss of function mutations in
TYMP, nor was there evidence of association between
this locus and Crohn’s disease susceptibility. The previ-
ously reported whole genome sequencing of Crohn’s
disease produced median coverage 4x genome-wide [4].
At this sequencing depth it is not possible to exclude
ultra-rare variants in TYMP in the 2513 patients who
were analysed. This would require high coverage se-
quencing. Their absence does, however, make it unlikely
that TYMP variation is a significant cause of Crohn’s
disease or that MNGIE phenocopying Crohn’s disease is
a common problem.
MNGIE has also recently been reported as a mimic
of refractory coeliac disease [6], a consideration in
the differential diagnosis of non-response to a gluten
free diet.
The late onset and mild phenotype observed in these
cases may reflect residual thymidine phosphorylase
activity and indicates that MNGIE may present later in
life than previously recognized [3].
Clinical features of MNGIE are an indirect conse-
quence of elevated circulating thymidine. This affects
intra-mitochondrial nucleoside levels leading to mito-
chondrial DNA (mtDNA) depletion and secondary
mtDNA mutations [7]. Whilst it is recognised that
febrile hypersensitivity reactions to azathioprine are not
uncommon, it is postulated that azathioprine may
further compromise mtDNA maintenance in MNGIE
(Fig. 3) through its action as antimetabolite purine
analogue [8]. Patient 1’s clinical deterioration was revers-
ible on cessation of azathioprine, possibly reflecting a
temporary exacerbation of mitochondrial impairment ra-
ther than formation of mtDNA mutations and subse-
quent cell death.
Alongside haemodialysis, platelet transfusion and allo-
geneic stem cell transplantation, liver transplantation
and nucleotide supplementation have been proposed as
treatments for MNGIE [9]. Concern over high mortality
rates following allogeneic stem cell transplantation has
led to the emergence of liver transplantation as a poten-
tial alternative, with high level of expression of thymi-
dine phosphorylase in the transplanted liver shown to
normalise the plasma thymidine and deoxyuridine levels
[10, 11]. Of these proposed treatments, Patient 1’s case
suggests that nucleotide supplementation may require
caution because manipulating mitochondrial nucleoside
pools could have unanticipated effects. Further investiga-
tion into the potential association of TYMP mutations
with febrile hypersensitivity reactions secondary to
azathioprine is needed.
It is important to consider measuring plasma thymi-
dine levels in cases of Crohn’s disease, particularly those
with white matter abnormalities identified on brain MRI,
which can accompany IBD [12].
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